Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACA Countdown: Details Emerging On Exchanges, Medicaid Expansion

This article was originally published in The Gray Sheet

Executive Summary

Open enrollment in state exchange plans kicks off Oct. 1 and expanded Medicaid eligibility Jan. 1, and many states offer a preliminary view of how coverage will play out under the Affordable Care Act in 2014.

You may also be interested in...



CMS Administrator Tavenner Emphasizes CMS And FDA Collaboration

While speaking Sept. 24 at the 2013 AdvaMed conference, CMS Administrator Marilyn Tavenner outlined CMS’ priorities over the next three years, focusing on access, quality and cost with a specific emphasis on CMS collaborations with FDA.

One-Third of Surveyed Device Firms Expect Increased Customer Base From ACA

The survey of 123 device executives sponsored by MassMEDIC probed the impact of the Affordable Care Act. Of the 33 percent who expect an increase in patient customer base from the insurance expansion, about one-quarter said it would be enough to counter the negative impact of the device excise tax.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel